-
-
-
-
-
-
-
CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
-
-
-
-
-
-
-
FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish F
-
-
-
-
-
-
-
Scholar Rock Holding Corp. (SRRK) Misses Q4 EPS by 189c
-
-
-
-
-
-
-
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress
-
-
-
-
-
-
-
Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability
-
-
-
-
-
-
-
Scholar Rock Holding Corp. (SRRK) Tops Q3 EPS by 10c
-
-
-
-
-
-
-
Scholar Rock Reports First Quarter 2021 Financial Results and Highlights Business Progress
-
1,197,273 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

